Figure 2 Cellular pathways implicated in CIPN

Slides:

Advertisements

Similar presentations

Table 3 Limb-girdle muscular dystrophy standardized data collection form and HPO mapping Thompson, R. & Straub, V. et al. (2016) Limb-girdle muscular dystrophies.

Advertisements

Nat. Rev. Neurol. doi:10/1038/nrneurol

Nat. Rev. Neurol. doi: /nrneurol

Targeting the PARP DNA repair pathway enhanced cytotoxicity induced by chemotherapy. Targeting the PARP DNA repair pathway enhanced cytotoxicity induced.

Figure 3 Life expectancy at birth in all countries included

Figure 2 Systemic abnormalities in AD

Nat. Rev. Neurol. doi: /nrneurol

Nat. Rev. Neurol. doi: /nrneurol

Figure 2 The US Centers for Disease Control and

Figure 4 Time course of the development of physiological changes

Figure 1 Carotid artery inflammation detected using 18F-FDG-PET

Nat. Rev. Neurol. doi: /nrneurol

Nat. Rev. Neurol. doi: /nrneurol

Figure 2 Monoamine synthesis and metabolism in neurons

Figure 1 Factors underlying metabolic alterations in osteoarthritis

Nat. Rev. Neurol. doi: /nrneurol

Figure 1 Candidate signalling pathways of irisin in adipocytes

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Neurol. doi: /nrneurol

Nat. Rev. Neurol. doi: /nrneurol

Nat. Rev. Neurol. doi: /nrneurol

Figure 2 Candidate signalling pathways of irisin in myocytess

Figure 3 Proportion of patients for whom NEDA

Figure 5 Number of AHSCT procedures for

Figure 3 Metabolic configurations of M1 and M2 macrophages

Figure 1 Physiological metabolism of Aβ in the brain and periphery

Figure 2 Co-stimulatory receptors as immunomodulatory targets

Figure 1 Diagnostic tiers of Parkinson disease as single disease

Figure 1 Allele frequency and effect size for ALS-associated genes

Figure 3 Drug cycling with collateral sensitivity

Nat. Rev. Neurol. doi: /nrneurol

Figure 3 Hypothetical mechanisms of smoking-associated

Figure 2 Algorithm for immunosuppressive treatment

Nat. Rev. Neurol. doi: /nrneurol

Figure 1 Principles of therapeutic ultrasound

Figure 2 Endocrine dysfunction in mitochondrial disease and their associated gene defects Figure 2 | Endocrine dysfunction in mitochondrial disease and.

Nat. Rev. Nephrol. doi: /nrneph

Nat. Rev. Neurol. doi: /nrneurol

Figure 1 Clinical correlates of neurodegeneration in MS

Figure 2 Median monthly launch price of a new anticancer drug,

Figure 3 Genetic pleiotropy in ALS

Nat. Rev. Neurol. doi: /nrneurol

Figure 1 The trajectory of cognitive ageing

Figure 4 Generation of tau seeds and spread of tau pathology

Nat. Rev. Neurol. doi: /nrneurol

Nat. Rev. Neurol. doi: /nrneurol

Figure 1 Anatomical patterns of neuropathy

Nat. Rev. Neurol. doi: /nrneurol

Nat. Rev. Neurol. doi: /nrneurol

Figure 5 Role of VEGF in stroke

Figure 3 Stroke-related deaths and DALYs by country development status

Figure 2 Age-specific prevalence of common comorbidities

Nat. Rev. Neurol. doi: /nrneurol

Figure 1 The node of Ranvier

Figure 3 Current model of immunopathogenesis in CIDP

Figure 6 Combining population-wide and high-risk strategies

Nat. Rev. Neurol. doi: /nrneurol

Figure 2 Logistical requirements for autologous

Figure 3 Potential interplay between physiological

Nat. Rev. Neurol. doi: /nrneurol

Figure 1 The VEGF family of growth factors

Figure 2 Pathophysiological mechanisms in LGMD

Adapted with permission from Tesfaye, S. , Boulton, A. J

Figure 1 Timing of the effects of deep brain stimulation

Figure 1 A large number of genes are potentially associated with CIPN

Figure 2 Impaired mitochondrial capacity and function in heart failure

Nat. Rev. Neurol. doi: /nrneurol

Figure 2 Histopathological features in CIDP

Figure 2 The main effects of adipokines on bone remodelling in osteoarthritis Figure 2 | The main effects of adipokines on bone remodelling in osteoarthritis.

Figure 2 Network connections of the hypothalamus

Presentation transcript:

Figure 2 Cellular pathways implicated in CIPN Figure 2 | Cellular pathways implicated in CIPN. Candidate genes investigated in most of the studies performed so far are mainly related to the metabolism and transport of chemotherapy drugs or to DNA repair. Other pathways and processes that might be implicated in chemotherapy-induced neuropathy (CIPN) include cell adhesion, energy production and redox homeostasis. Clear understanding of how these processes contribute to CIPN is currently lacking. Argyriou A. A. et al. (2017) Chemotherapy-induced peripheral neurotoxicity: management informed by pharmacogenetics Nat. Rev. Neurol. doi:10.1038/nrneurol.2017.88